Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMC-S118AI in Type 1 Diabetes
NCT07493122Phase 1Not yet recruiting
- Sponsor
- Immunocore
- Start
- Apr 2026
- Primary completion
- Nov 2030
- Modality
- Fc-Fusion Proteins
01
Overview
Phase 1 trial of IMC-S118AI in type 1 diabetes mellitus (T1D) (2 arms), sponsored by Immunocore. Primary endpoints: Number of participants with ≥1 treatment-emergent serious adverse event up to 60 weeks, Number of participants with ≥1 treatment-emergent adverse event up to 45 weeks and 4 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
IMC-S118AI
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT07493122.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07493122.